NEULANDLAB vs WANBURY: Stock Comparison

Neuland Laboratories Limited vs Wanbury Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Neuland Laboratories Limited is the larger company by market capitalisation. Neuland Laboratories Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Wanbury Ltd shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Neuland Laboratories Limited and Wanbury Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NEULANDLAB is more favourable on 8 of 13 scored metrics and WANBURY on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NEULANDLAB is the larger company
₹24,223 Cr vs ₹1,091 Cr
P/E Ratio
WANBURY has a lower P/E
0x vs 66.9x
P/B Ratio
WANBURY has a lower P/B
0x vs 12.99x
EPS
NEULANDLAB has higher earnings per share
₹293.13 vs ₹13.1
Dividend Yield
NEULANDLAB has a higher dividend yield
0.06% vs 0%
Revenue Growth (TTM YoY)
NEULANDLAB has faster revenue growth
136.4% vs -19.2%
EPS Growth (TTM YoY)
NEULANDLAB has faster EPS growth
664.4% vs 0%
Qtr Sales Growth
NEULANDLAB has stronger quarterly sales growth
136% vs 24.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNEULANDLABWANBURY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNEULANDLABWANBURY
Live Price₹18,871₹312.45
Day Change-0.65%-5.1%
Volume15,5932.85 L
52-Week High₹20,089₹358.85
52-Week Low₹11,500₹161.5
Distance from 52W High-6.06%-12.93%

Valuation

MetricNEULANDLABWANBURY
Market Cap₹24,223 Cr₹1,091 Cr
P/E Ratio66.9x0x
P/B Ratio12.99x0x
EPS₹293.13₹13.1
Book Value₹1,460.02₹18.1
Dividend Yield0.06%0%

Growth

MetricNEULANDLABWANBURY
Revenue Growth (TTM YoY)136.4%-19.2%
EPS Growth (TTM YoY)664.4%0%
Qtr Sales Growth136%24.5%
Qtr Profit Growth665%1,197%

Profitability & Leverage

MetricNEULANDLABWANBURY
ROE21.4%76.5%
ROCE26.6%36.6%
Net Margin17.99%10.17%
Operating Margin28.4%14%
Debt to Equity0.16x3.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricNEULANDLABWANBURY
Promoter Holding32.62% 0.01 pp34.36%
FII Holding21.08% 0.62 pp0.89% 0.3 pp
DII Holding16.51% 0.67 pp0.06% 0.06 pp
Public Holding29.79% 1.28 pp56.03% 0.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Neuland Laboratories Limited and Wanbury Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.